专利检索_羧酸酰胺酸部分的碳架进一步被氧原子取代专利检索_羧酸酰胺酸部分的碳架进一步被氧原子取代专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
201	Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics	US11449381	2006-06-08	US08686045B2	2014-04-01	Frank M. Longo; Stephen M. Massa
Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.
202	Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same	US12865082	2009-01-28	US08557872B2	2013-10-15	Song Seok Shin; Jin Kwan Kim; Sun-Young Kim; Ki-Wha Lee; Byoung Young Woo; Joo-Hyun Moh; Yeon Su Jeong; Kyung Min Lim; Jin Kyu Choi; Hyun-Ju Koh; Young-Ho Park
This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same.The present disclosure provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.
203	N-phenylacetamide inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof	US12717998	2010-03-05	US08513307B2	2013-08-20	Thibaud Portal
Novel N-phenylacetamide compounds of formula (I): and cosmetic and pharmaceutical compositions containing same are useful for treating disorders of the sebaceous gland, e.g., acne, or have cosmetic applications.
204	Stable dosage forms of levomilnacipran	US13006993	2011-01-14	US08481598B2	2013-07-09	Rahul Surana; Murali Divi; Anil Chhettry
The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.
205	Method of preparing chiral cyclic β-aminocarboxamides	US12301131	2007-05-15	US08466318B2	2013-06-18	Guenter Linz; Gerd Kraemer; Zeno A. Leuter; Markus Ostermeier; Werner Rall; Claudia Ochs; Rolf Schmid
The present invention encompasses a process for preparing compounds of formula (1), wherein a compound of formula (2) is reacted in the presence of a catalyst and a solvent under hydrogen pressure to form a compound of formula (1) and wherein A and R1—R4 are defined herein.
206	Methods for concomitant administration of colchicine and a second active agent	US13454286	2012-04-24	US08445541B2	2013-05-21	Matthew W. Davis
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
207	Substituted oligo- or polythiophenes	US12921176	2009-03-06	US08436208B2	2013-05-07	Hans Jürg Kirner; Frank Bienewald; Jean-Charles Flores; Olivier Frédéric Aebischer
A process for the preparation of a substituted 2,2′-dithiophene is described, which process comprises the steps (a), (c) and optional steps (b) and (d): a reaction of a compound of the formula: with a suitable lithium organic compound, preferably Li-alkyl or Li-alkylamide; b) optional exchange of lithium against another metal selected from Mg1 Zn and Cu; c) reaction of the metallated intermediate obtained in step (a) or (b) with a suitable electrophil, which is CO2 or an aldehyde (addition reaction), or a compound Y′—R17 or Y′—R18-Z (substitution reaction), where R17 and R18 are as defined in claim 1; and optionally d) modification of the product obtained in step (c), e.g. by introducing one or more conjugating moieties Y ring closure between suitable monovalent residues R17, exchange or extension of functional groups or substituents such as addition to carbonyl or substitution of carbonyl in R17 or R18. The products, including or corresponding polymers, are excellent conducting materials
208	Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase	US13170998	2011-06-28	US08426644B2	2013-04-23	Paul Q. Anziano
The present invention is directed to methods of modulating the activity of an isoform of manganese superoxide dismutase which is useful for the treatment of diseases such as neurodegenerative diseases and heart failure.
209	Colchine compositions and methods	US13452277	2012-04-20	US08415396B1	2013-04-09	Matthew W. Davis; Hengsheng Feng
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
210	Colchicine compositions and methods	US13451328	2012-04-19	US08415395B1	2013-04-09	Matthew W. Davis; Hengsheng Feng
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
211	Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders	US12309361	2007-07-17	US08377990B2	2013-02-19	Abraham Nudelman; Ada Rephaeli; Irit Gil-Ad; Abraham Weizman
A novel use of conjugates of psychotropic drugs (e.g., antidepressants or anti-epileptic drugs) and organic acids such as GABA in the treatment of pain is disclosed. A novel GABA conjugate and uses thereof is also disclosed.
212	Compounds	US12740216	2008-10-30	US08293798B2	2012-10-23	Alessandra Gaiba; Susan Roomans; Martin Edward Swarbrick
A compound of formula (I) or salts thereof, wherein R1, R2, R3, R4, n and X are as defined in the specification; a process for preparing such compounds, a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.
213	Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent	US10492648	2002-10-15	US08178121B2	2012-05-15	Tho Nguyen-Xuan
The present invention refers to ready-to-use highly stable paracetamol injectable solutions, prepared by mixing paracetamol, water, propylene glycol, and a citrate buffer. (pH 4.5 to 6.5), and by heating said solution under preset conditions. The resulting solution may be stored for an extended period of time within a wide range of temperatures, with no paracetamol precipitation and/or its chemical modification.
214	Polychromic substances and their use	US12863625	2009-01-22	US08083973B2	2011-12-27	Anthony N Jarvis
A compound which undergoes a color change upon irradiation, and which has the general structure: X—C≡C—C≡C—Y—(CO)n-QZ wherein X is H, alkyl or —Y—(CO)n-QW; each Y is the same or a different divalent alkylene group; Q is O, S or NR; R is H or alkyl; W is H, alkyl or Z; each Z is the same or a different unsaturated alkyl group; and each n is 0 or 1.
215	Methods for concomitant administration of colchicine and macrolide antibiotics	US13090697	2011-04-20	US08039515B2	2011-10-18	Matthew W. Davis
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
216	Colchicine compositions and methods	US12687406	2010-01-14	US07981938B2	2011-07-19	Matthew W. Davis
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
217	Large-scale synthesis of selective androgen receptor modulators	US10754626	2004-01-12	US07968721B2	2011-06-28	Duane D. Miller; Karen A. Veverka; Kiwon Chung
This invention relates to a process for preparing a selective androgen receptor modulator (SARM) compound represented by the structure of formula I: wherein X is O; and T, Z, Y, Q, R and R1 are defined herein. The process includes coupling between an amide of formula II and a phenol of formula III followed by a purification step consisting of precipitating the compound of formula (I) in a mixture of alcohol and water alone.
218	Modulation of pathogenicity	US12005783	2007-12-28	US20100280034A1	2010-11-04	Aldo Ammendola; Katharina Aulinger-Fuchs; Astrid Gotschlich; Bernd Kramer; Martin Lang; Wael Saeb; Udo Sinks; Andreas Wuzik
The present invention relates to the use of compounds of the general Formula (XIII): wherein A7 is C═O, C═S, SO2, CH—OR13, C═NR12, or CH2—CHOR13; A8 is C(R14)2, O, S, or NR12; A9 is C═O, C═S, SO2, CH—OR13, C═NR12, or CH2—CHOR13; m is 0, or 1 q is 0, or 1 r is 0, or 1 R12 is H, CH3, CH2—CH3, C6H5, OCH3, OCH2—CH3, OH, or SH; R13 is H, CH3, or CH2—CH3; R14 is H, alkyl, alkoxy, OH, or SH;
219	Transfection reagents	US11040662	2005-01-21	US07601872B2	2009-10-13	Yongliang Chu; Malek Masoud; Gulilat Gebeyehu
Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)l, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1-L′-X2-Z or -Z; R1-R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and wherein at least one of R1, R3, R4 and R6 is a straight chain or branched, cyclic, alkyl, alkenyl, alkynyl or aryl group; and anyone of R1, R3, R4 and/or R6 may optionally be covalently linked with each other, with Y or with L when L is C or CH to form a cyclic moiety; Z is selected from the group consisting of amine, spermiyl, carboxyspermiyl, guanidyl, spermidinyl, putricinyl, diaminoalkyl, pyridyl, piperidinyl, pyrrolidinyl, polyamine, amino acid, peptide, and protein; X1 and X2, independently of one another, are selected from the group consisting of NH, O, S, alkylene, and arylene; L′ is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, alkylene ether, and polyether; D is Q or a bond; A1 and A2, independently of one another, are selected from the group consisting of CH2O, CH2S, CH2NH, C(O), C{NH), C(S) and (CH2)t; X is a physiologically acceptable anion; m, n, r, s, u, v, w and y are 0 or 1, with the proviso that when both m and n are 0 at least one of r, s, u and y is other than 0; i, j, k, l, p and are integers from 0 to about 100; q is an integer from 1 to about 1000; and a is the number of positive charge divided by the valence of the anion.
220	Inositol-based molecular transporters and processes for the preparation thereof	US10565164	2004-08-06	US07589072B2	2009-09-15	Sung-Kee Chung; Ock-Younm Jeon; Kaustabh Kumar Maiti; Seok-Ho Yu
Inositol derivatives in accordance with the present invention are effective in significantly enhancing the transportation of various therapeutic molecules across a biological membrane, which may include the plasma membrane, nuclear membrane or blood-brain barrier.

6 7 8 9 10 11 12 13 14 15

该功能需要专业版企业版VIP权限，您可以：